Figure 3 :The prevalence of ARD patients after using anti-rheumatic drugs from the perspective of the main drugs. (A) GC, (B) bDMARDs, (C) csDMARDs, (D) anti-TNF therapy.
From the perspective of the primary drugs, the prevalences of SLE patients mainly using GC and csDMARDs were 0.101(95%CI:0.035-0.166) and 0.095(95%CI:0.041-0.149), respectively, using GC had a higher prevalence and using csDMARDs had a lower prevalence. The prevalence of vasculitis patients using GC was 0.081(95%CI:0.005-0.157), and using bDMARDs and csDMARDs were both 0.047(95%CI:-0.021 to 0.114), respectively, using GC have the highest prevalence. The prevalence of AS patients using bDMARDs was 0.074(95%CI:0.039-0.108). Due to the small number of studies and the limitations of statistical methods, the prevalences of RA patients using bDMARDs and csDMARDs were both 0.028(95%CI:0.019-0.037). Besides, The prevalence of PsA patients using bDMARDs was 0.289(95%CI:-0.099 to 0.677), suggesting the prevalence in PsA was not statistically significant(Figure p7).